“the therapeutic application and potential value of GLP-1RAs in diseases other than diabetes has become a research hotspot. Interestingly, GLP-1RAs have been reported to activate the metabolism of brown fat and increase the energy expenditure in rodents through exercise activities independent of the sympathetic nervous system pathway (3). Liraglutide has been approved by the United States Food and Drug Administration (FDA) for long-term weight management (4). Moreover, GLP-1RAs have been shown to exert many beneficial effects on vascular endothelial cells. For instance, GLP-1RAs were demonstrated to reduce the risk of cardiovascular events (5) by decreasing the blood pressure (6), improving microvascular function, and reducing inflammation (7). Further, GLP-1RAs play a neuroprotective effect by stimulating the differentiation of nerve cells and inhibiting neuroinflammation (8), while they were also reported to inhibit liver inflammation (9). These findings indicated that in addition to playing a role in the treatment of diabetes, GLP-1RAs can also be used in the treatment of other diseases, such as certain neurological diseases, cardiovascular diseases (CVDs), and diseases related to metabolic disorders. Many studies on the correlation between the function of GLP-1RAs and the development and progression of tumors are also underway. Related studies (10) have found that GLP-1RAs can inhibit the PI3K/AKT/mTOR and ERK/MAPK pathways, thereby inhibiting the growth of prostate cancer; however, whether GLP-1RAs increase the risk of pancreatitis remains controversial (11). We here attempted to systematically review the mechanisms of action and therapeutic value of GLP-1RAs.”


GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Front. Endocrinol., 23 August 2021